These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
979 related articles for article (PubMed ID: 15125740)
1. Occult metastases in axillary lymph nodes as a predictor of survival in node-negative breast carcinoma with long-term follow-up. Reed W; Bøhler PJ; Sandstad B; Nesland JM Breast J; 2004; 10(3):174-80. PubMed ID: 15125740 [TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer. Loya A; Guray M; Hennessy BT; Middleton LP; Buchholz TA; Valero V; Sahin AA Cancer; 2009 Apr; 115(8):1605-12. PubMed ID: 19197997 [TBL] [Abstract][Full Text] [Related]
3. Biological significance of occult micrometastases in histologically negative axillary lymph nodes in breast cancer patients using the recent American Joint Committee on Cancer breast cancer staging system. Kahn HJ; Hanna WM; Chapman JA; Trudeau ME; Lickley HL; Mobbs BG; Murray D; Pritchard KI; Sawka CA; McCready DR; Marks A Breast J; 2006; 12(4):294-301. PubMed ID: 16848838 [TBL] [Abstract][Full Text] [Related]
4. The prognostic importance of immunohistochemically detected node metastases in resected esophageal adenocarcinoma. Waterman TA; Hagen JA; Peters JH; DeMeester SR; Taylor CR; Demeester TR Ann Thorac Surg; 2004 Oct; 78(4):1161-9; discussion 1161-9. PubMed ID: 15464464 [TBL] [Abstract][Full Text] [Related]
5. Clinical implications of occult metastases and isolated tumor cells in sentinel and non-sentinel lymph nodes in early breast cancer patients: serial step section analysis with long-term follow-up. Takeshita T; Tsuda H; Moriya T; Yamasaki T; Asakawa H; Ueda S; Sato K; Aida S; Tamai S; Matsubara O; Hase K; Yamamoto J Ann Surg Oncol; 2012 Apr; 19(4):1160-6. PubMed ID: 21989659 [TBL] [Abstract][Full Text] [Related]
6. Occult metastases in the sentinel lymph nodes of patients with early stage breast carcinoma: A preliminary study. Dowlatshahi K; Fan M; Bloom KJ; Spitz DJ; Patel S; Snider HC Cancer; 1999 Sep; 86(6):990-6. PubMed ID: 10491525 [TBL] [Abstract][Full Text] [Related]
7. Pathologic analysis of sentinel and nonsentinel lymph nodes in breast carcinoma: a multicenter study. Weaver DL; Krag DN; Ashikaga T; Harlow SP; O'Connell M Cancer; 2000 Mar; 88(5):1099-107. PubMed ID: 10699901 [TBL] [Abstract][Full Text] [Related]
8. Early distant relapse in "node-negative" breast cancer patients is not predicted by occult axillary lymph node metastases, but by the features of the primary tumour. Colpaert C; Vermeulen P; Jeuris W; van Beest P; Goovaerts G; Weyler J; Van Dam P; Dirix L; Van Marck E J Pathol; 2001 Apr; 193(4):442-9. PubMed ID: 11276002 [TBL] [Abstract][Full Text] [Related]
9. Omitting axillary lymph node dissection in sentinel node negative breast cancer patients is safe: a long term follow-up analysis. Torrenga H; Fabry H; van der Sijp JR; van Diest PJ; Pijpers R; Meijer S J Surg Oncol; 2004 Oct; 88(1):4-7; discussion 7-8. PubMed ID: 15384064 [TBL] [Abstract][Full Text] [Related]
10. The incidence and significance of micrometastases in lymph nodes of patients with ductal carcinoma in situ and T1a carcinoma of the breast. Broekhuizen LN; Wijsman JH; Peterse JL; Rutgers EJ Eur J Surg Oncol; 2006 Jun; 32(5):502-6. PubMed ID: 16569492 [TBL] [Abstract][Full Text] [Related]
11. Sentinel lymph node biopsy alone has no adverse impact on the survival of patients with breast cancer. Takei H; Suemasu K; Kurosumi M; Horii Y; Ninomiya J; Yoshida M; Hagiwara Y; Inoue K; Tabei T Breast J; 2006; 12(5 Suppl 2):S157-64. PubMed ID: 16958996 [TBL] [Abstract][Full Text] [Related]
12. Histological detection of minimal metastatic involvement in axillary sentinel nodes: a rational basis for a sensitive methodology usable in daily practice. Fréneaux P; Nos C; Vincent-Salomon A; Genin P; Sigal-Zafrani B; Al Ghuzlan A; Birolini MJ; Clough K; Sastre-Garau X Mod Pathol; 2002 Jun; 15(6):641-6. PubMed ID: 12065778 [TBL] [Abstract][Full Text] [Related]
13. Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry. Chagpar A; Middleton LP; Sahin AA; Meric-Bernstam F; Kuerer HM; Feig BW; Ross MI; Ames FC; Singletary SE; Buchholz TA; Valero V; Hunt KK Cancer; 2005 Apr; 103(8):1581-6. PubMed ID: 15747375 [TBL] [Abstract][Full Text] [Related]
14. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy. Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422 [TBL] [Abstract][Full Text] [Related]
15. The prognostic impact of occult nodal metastasis in early breast carcinoma. Park D; Kåresen R; Naume B; Synnestvedt M; Beraki E; Sauer T Breast Cancer Res Treat; 2009 Nov; 118(1):57-66. PubMed ID: 19219629 [TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical detection of lymph node metastases in node-negative breast cancer patients. Kohlberger P; Gantert M; Volk-Orlowska T; Kieback DG; Gitsch G Anticancer Res; 2001; 21(1B):697-9. PubMed ID: 11299828 [TBL] [Abstract][Full Text] [Related]
17. Micrometastases in axillary lymph nodes and bone marrow of lymph node-negative breast cancer patients--prognostic relevance after 10 years. Gebauer G; Fehm T; Merkle E; Jaeger W; Mitze M Anticancer Res; 2003; 23(5b):4319-24. PubMed ID: 14666645 [TBL] [Abstract][Full Text] [Related]
18. [Value of cancer-related oncoprotein expression as prognostic factors in breast-cancer with one to three axillary lymph nodes positive]. Zhang G; Tsuda H; Adachi I; Fukutomi T; Yamamoto H; Hirohashi S Gan To Kagaku Ryoho; 1996 Mar; 23 Suppl 1():66-74. PubMed ID: 8702314 [TBL] [Abstract][Full Text] [Related]
19. [Axillary skip metastases in breast cancer]. Sun JY; Ning LS Zhonghua Zhong Liu Za Zhi; 2008 May; 30(5):352-5. PubMed ID: 18953834 [TBL] [Abstract][Full Text] [Related]
20. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer. Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]